Mineralys Therapeutics Selected For Oral Poster Presentation Of Target-HTN Phase 2 Trial Results At 2023 AHA Hypertension Scientific Sessions
Portfolio Pulse from Happy Mohamed
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled hypertension or resistant hypertension at the 2023 American Heart Association Hypertension Scientific Sessions. Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension and CKD.
September 05, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mineralys Therapeutics' selection to present the results of its Phase 2 trial for lorundrostat at a major conference could potentially increase investor interest and confidence in the company.
The presentation of positive trial results at a major conference can often lead to increased visibility and credibility for a company's product, potentially leading to increased investor interest and a positive impact on the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100